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Abstract
Background: This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete
transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients.
Methods: The study enrolled 178 HCC patients initially treated with TACE between 2006 and 2011. Patients were
included if they had Barcelona Clinic Liver Cancer stage 0 or A, ≤3 nodules with a total sum of longest diameter
≤10 cm, Child-Turcotte-Pugh score of ≤7, no major vessel invasion, and no extra-hepatic metastases.
Results: Twenty-four patients achieved a complete response to TACE (group 1). Among those with incomplete
response, 47 patients received other curative treatments (group 2), 37 received SABR (group 3), and 70 received
non-curative treatments (group 4). The 2–year overall survival (OS) rates for groups 1, 2, 3, and 4 were 88 %, 81 %,
73 %, and 54 %, respectively. The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively.
Conclusions: Patients treated with SABR after incomplete TACE had similar survival outcomes to those achieving
complete response to TACE or receiving curative treatments. However, patients receiving non-curative treatments
had significantly lower survival rates than the other groups. Therefore, if SABR was indicated at the initial diagnosis,
it might be recommended after TACE failure.
Keywords: Hepatocellular carcinoma, Radiotherapy, Stereotactic ablative radiotherapy, Transcatheter arterial
chemoembolization
Background
The primary treatment for hepatocellular carcinoma
(HCC) is surgery, including hepatic resection and liver
transplantation, which results in 5-year survival rates of
30–70 % [1]. However, <20 % of HCC patients are eli-
gible for surgery. In unresectable cases, local therapies
such as radiofrequency ablation (RFA) or percutaneous
ethanol injection (PEI) are reportedly effective, but not
all patients are eligible for these treatments due to the
tumor’s percutaneous inaccessibility, its invisibility via
ultrasonography, or bleeding risks. Transcatheter arterial
chemoembolization (TACE) has been widely used as the
first-line non-curative therapy for HCC cases that are
non-surgical or unsuitable for local ablative therapies
[2]. However, TACE alone rarely produces a complete
response, and additional treatments are often required.
Multiple repetitive sessions of TACE have been widely
performed in Korea, but such treatments deteriorate
liver function, increase TACE-related adverse effects,
and offer less therapeutic efficacy due to vascularity de-
crease [3]. Therefore, various modalities such as RFA,
PEI, sorafenib, conventional radiotherapy (RT), and
stereotactic ablative radiotherapy (SABR) have been sug-
gested in addition to TACE, but a definitive guideline
has not been established [4, 5].
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The role of RT in HCC is limited owing to the liver’s
low tolerance to radiation and the risk of radiation-
induced liver damage [6, 7]. However, recent radiothera-
peutic developments have gradually expanded the indi-
cations for external beam radiotherapy from palliative to
curative with high doses of radiation safely delivered to
the tumor while avoiding adverse effects to the liver
function. In several studies on three-dimensional con-
formal radiotherapy (3D-CRT) to primary HCC, sub-
stantial effects of RT have been observed [8–10]. With
the introduction of SABR, it is now possible to accur-
ately deliver more radiation doses to tumors using fewer
fractions while sparing the normal liver tissue [11, 12].
Recent clinical data have demonstrated the feasibility of
SABR for HCC treatment with high local control (LC)
and overall survival (OS) rates and low treatment-related
severe toxicities [13–21].
However, there remains a lack of randomized studies
comparing the effects of TACE combined with RT and
those of TACE alone. Although several phase II trials of
SABR have reported outstanding results, including LC
rates of > 90 % and 5-year OS of > 50 % in well selected
cases of HCC, RT is still not endorsed as a curative
treatment option for HCC in most guidelines or consen-
sus strategies [1, 22, 23]. Therefore, this retrospective
study aimed to provide the basis for initiating a random-
ized trial to investigate whether a combination of SABR
and TACE would improve the long-term OS compared
with TACE alone. The survival outcomes of TACE plus
SABR were compared with those of other treatment mo-
dalities combined with TACE or TACE alone.
Methods
Patients
Between January 2006 and December 2011, a total of
832 consecutive HCC patients were treated with TACE
at Korea Institute of Radiological and Medical Sciences.
Of those, patients receiving curative treatments such as
surgery or RFA at initial diagnosis were excluded, and
only those initially treated with TACE were included in
this study. All patients’ medical records were retrospect-
ively reviewed. A total of 178 patients met the following
eligibility criteria: (1) Barcelona Clinic Liver Cancer
(BCLC) stage 0 or A, (2) single or multiple lesions (≤3
nodules), (3) each tumor measuring ≤10 cm at the lon-
gest diameter (LD), with the sum of LD being ≤10 cm,
(4) Child-Turcotte-Pugh (CTP) score of ≤7, (5) no major
vessel invasion, and (6) no extrahepatic metastases. The
exclusion criteria included (1) diffuse infiltrative tumor
type, (2) liver cirrhosis-associated complications such as
uncontrolled ascites or encephalopathy, (3) severe co-
morbidities, (4) previous RT to the upper abdomen, and
(5) other malignancies within 5 years. These are our
institutional criteria for curative SABR in HCC patients
[4, 19]. This study was approved by our institutional re-
view board.
TACE
TACE was performed with an infusion of a lipiodol and
doxorubicin mixture. Tumor response to TACE was
evaluated using computed tomography (CT) 1 month
after TACE. Although the definition of TACE failure has
been proposed by the Japan Society of Hepatology [23],
there is no internationally accepted consensus on the
definition of TACE failure or TACE refractoriness cri-
teria. In our study, incomplete response to TACE was
defined as disease progression, incomplete tumor filling
by the lipiodol-doxorubicin mixture on CT images. Dis-
ease progression included residual viable tumors, pro-
gression of existing lesions, or development of new
lesions. Patients’ final response to TACE was assessed by
a hepatologist. Although current evidence suggests that
1 cycle of TACE may not be sufficient for effective treat-
ment and repeating TACE prolongs survival [24], no
guidelines are available on the criteria for repeating
TACE. In this study, if TACE yielded a complete re-
sponse, no additional treatment was given, and the pa-
tient was followed up by regular evaluations. In cases of
incomplete response, additional TACE was performed,
or a change in treatment strategy was conducted.
SABR
SABR was performed as previously described [4, 19]. Pa-
tients were treated using either a CyberKnife (Accuray
Inc., Sunnyvale, CA, USA) or a RapidArc (Varian Med-
ical Systems, Palo Alto, CA, USA) system. Gold fiducials
inserted near the spine closest to the lesion were used
for tracking in patients treated with CyberKnife. For pa-
tients treated with RapidArc, gold fiducials inserted in
the liver near the tumor or lipiodol uptake were used as
markers for image guidance with the cone-beam CT. To
compensate for breathing motion, simulation CT with
abdominal compression was performed, and both slow
and helical CT images were obtained with contrast
medium. The gross tumor volume (GTV) was defined in
the slow CT set as the viable tumor with the contrast
medium uptake including the embolization material.
These slow CT images included the respiratory move-
ment of the target, therefore the GTV used for planning
was larger than the actual gross tumor and was referred
to as the internal target volume (ITV). To better delin-
eate the tumor volumes, magnetic resonance imaging
(MRI) images were used as references on a regular basis.
A margin of 0–4 mm was added to the ITV for the plan-
ning target volume (PTV). SABR doses were prescribed
at an isodose line (70–80 % of the maximum dose) that
covered at least 97 % of the PTV.
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Treatment doses were determined according to previ-
ously described protocols [4, 19, 20]. A total dose of 40–
60 Gy (median 56 Gy) in 3–5 fractions was prescribed.
Briefly summarizing the previous protocols, the final
prescribed doses were 60 Gy in 3 fractions, but the dos-
ages were reduced by 0.5 or 1 Gy per fraction until the
normal tissue constraints were allowed. For the normal
liver, at least 700 ml of normal liver (entire liver minus the
cumulative GTV) should not receive a total dose ≥ 17 Gy
in 3 fractions. For the spinal cord, the maximum dose
should not exceed 18 Gy in 3 fractions. For the esophagus,
the maximum dose should not exceed 24 Gy in 3 fractions.
In addition, although other normal tissue constraints were
not considered, dosages to the kidney, intestine, and stom-
ach were restricted to the lowest levels possible.
Evaluation and statistical analysis
Baseline patient and tumor characteristics were compared
among groups using the one-way analysis of variance or
the Kruskal-Wallis test as appropriate. Survival was calcu-
lated from the date of the initial TACE using the Kaplan-
Meier method, and intergroup comparisons were per-
formed using the log-rank test. Univariate analysis was
performed using the log-rank test to identify the signifi-
cant prognostic factors for survival. The Cox regression
model was applied to all potentially significant variables
for the multivariate analysis. For all analyses, two-sided
tests of significance were used with P values <0.05 consid-
ered significant. All statistical analyses were performed
using the Statistical Package for the Social Sciences (ver-
sion 14.0; SPSS, Inc. Chicago, IL, USA).
Results
Baseline patient characteristics
Of the 832 consecutive HCC patients treated with TACE,
178 met all eligibility criteria. Our enrollment suggests that
among patients currently treated with TACE, approximately
21 % (or higher if those initially treated with surgery or
other local ablative therapies are included) may be eligible
for SABR. Twenty-four (14 %) patients achieved a complete
response to TACE as the primary treatment (group 1;
complete TACE group). The remaining 154 (86 %) patients
showed incomplete response and were further treated with
other modalities. Of these, 47 (26 %) patients further re-
ceived curative treatments (group 2; incomplete TACE +
curative Tx group) such as surgery, RFA, or PEI; 37 (21 %)
were treated with SABR (group 3; incomplete TACE +
SABR group); and 70 (39 %) received non-curative treat-
ments (group 4; incomplete TACE + non-curative Tx
group) such as repeated TACE, sorafenib, and chemother-
apy (Fig. 1). Among the 47 group 2 patients, 35 (75 %) re-
ceived surgery including resection and liver transplantation,
11 (23 %) received RFA, and 1 (2 %) received PEI. Among
the 70 group 4 patients, 66 (95 %) received repeated TACE,
3 (4 %) received sorafenib, and 1 (1 %) received chemother-
apy. The median number (range) of previous TACE ses-
sions performed for groups 1, 2, 3, and 4 patients were 1
(1–4), 1 (1–5), 2 (1–6), and 2 (1–13), respectively.
No significant differences in age, sex, BCLC stage, and
tumor size were observed among the 4 groups (Table 1).
However, statistically significant differences in CTP scores
were observed between groups 2 and 4 (P = 0.004). Fur-
thermore, patient characteristics did not differ among
Fig. 1 Study design flowchart. Twenty-one percent of the patients treated with TACE met the eligibility criteria, which is also the criteria for SABR
with curative intent in our institute. These patients were divided into 4 groups according to the further treatment received. Abbreviations: HCC,
hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization; Tx, treatment; SABR, stereotactic ablative radiotherapy. * Percentage of
patients from the total number of patients receiving TACE (n = 832). † Percentage of patients from those meeting the eligibility criteria (n = 178)
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groups 1, 2, and 3, or between groups 3 and 4. Nonethe-
less, group 1 patients had relatively lower BCLC stages and
smaller tumors than the other groups, whereas those in
group 2 had lower CTP scores and smaller tumors (Fig. 2).
Overall survival
The median follow up duration after the initial TACE for
all patients was 35 months (range, 2–83 months). The OS
rates at 2 and 5 years were 88 % and 50 % for group 1,
81 % and 58 % for group 2, 73 % and 53 % for group 3,
and 54 % and 28 % for group 4, respectively (Fig. 3). No
significant differences in OS rates were observed among
groups 1, 2, and 3. However, group 4 showed a signifi-
cantly different OS rate compared with the other 3 groups
(vs. group 1, P = 0.010; vs. group 2, P = 0.001; vs. group 3,
P = 0.040; Table 2).
In univariate analysis, CTP score, tumor size, and treat-
ment options were identified as significant prognostic fac-
tors for OS (Table 2). A CTP score of 7 was associated with
significantly lower survival rates than CTP scores of 5 or 6.
Tumors >3 cm had significantly lower survival rates than
those <3 cm. In multivariate analysis, CTP score and treat-
ment options were identified as significant prognostic fac-
tors. Group 4 showed significantly lower survival rates than




Curative Tx SABR Non-curative Tx
Age 0.622
Range (median, years) 41–83 (55) 35–77 (60) 42–74 (59) 24–84 (59)
Sex 0.426
Male 14 (58) 33 (70) 29 (78) 49 (70)
Female 10 (42) 14 (30) 8 (22) 21 (30)
BCLC stage 0.135
0 9 (38) 8 (17) 6 (16) 12 (17)
A 15 (63) 39 (83) 31 (84) 58 (83)
CTP score 0.040
5 18 (75) 42 (89) 26 (70) 47 (67)
6 3 (13) 5 (11) 7 (19) 16 (23)
7 3 (13) 0 ( 0) 4 (11) 7 (10)
Tumor size 0.073
Range (median, cm) 0.5–8 (2.1) 1–8 (2.8) 0.8–10 (3.4) 0.5–10 (3.8)
0.1–3.0 cm 19 (79) 32 (68) 18 (49) 36 (51)
3.1–10.0 cm 5 (21) 15 (32) 19 (51) 34 (49)
Abbreviations: TACE transcatheter arterial chemoembolization, Tx treatment, SABR stereotactic ablative radiotherapy, BCLC Barcelona Clinic Liver Cancer,
CTP Child-Turcotte-Pugh









































































Fig. 2 Tumor characteristics of each treatment group. a By Barcelona Clinic Liver Cancer (BCLC) stage; (b) By Child-Turcotte-Pugh (CTP) score; (c)
By tumor size
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the other 3 groups, but no significant differences were ob-
served among groups 1, 2, and 3.
Discussion
In previous phase I and phase II studies conducted at
our institute [4, 19], the feasibility of SABR for the treat-
ment of primary HCC with incomplete response to
TACE has been demonstrated with a 2-year LC rate of
94.6 % and a 2-year OS rate of 68.7 %. In the long term
follow up study [20], LC and OS rates at 5 years were
82 % and 39 %, respectively. Furthermore, at the last
follow-up (4.5 years), patients receiving high-dose SABR
(>54 Gy) reported a 100 % LC rate and a 68 % OS rate,
which were comparable to RFA outcomes. Based on the
results of these studies of SABR, HCC cases with a CTP
score of 5–7, total sum of tumor size < 10 cm, and ≤ 3
Fig. 3 Patients’ overall survival for each treatment group from the time of the first TACE treatment. No significant differences in overall survival
rates were observed among groups 1, 2, and 3. However, group 4 showed a significantly inferior overall survival rate compared with the other 3
groups. Abbreviations: TACE, transcatheter arterial chemoembolization; Tx, treatment; SABR, stereotactic ablative radiotherapy
Table 2 Prognostic factors for overall survival
Factor 5-year
OS (%)
Univariate analysis Multivariate analysis
P-value HR (95 % CI)
Treatment option
Complete TACE 50
TACE + Curative Tx 58 0.843 1.100 (0.521–2.324)
TACE + SABR 53 0.493 1.207 (0.573–2.545)
TACE + Non-curative Tx 28 0.010 2.421 (1.248–4.498)
BCLC stage
0 54
A 42 0.139 -
CTP score
5 48
6 33 0.128 1.037 (0.622–1.729)
7 29 0.013 2.229 (1.147–4.332)
Tumor size (cm)
0.1–3.0 49
3.1–10.0 32 0.008 -
Abbreviations: OS overall survival, TACE transcatheter arterial chemoembolization, Tx treatment, SABR stereotactic ablative radiotherapy, BCLC Barcelona Clinic Liver
Cancer, CTP Child-Turcotte-Pugh
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nodules seem to be feasible for curative SABR. There-
fore, to investigate whether the addition of SABR to
TACE offers a survival benefit to HCC patients with in-
complete response to TACE, we enrolled those meeting
the above-mentioned eligibility criteria. In this study, the
addition of SABR after incomplete TACE demonstrated
significant survival benefits compared with additional
non-curative treatments such as repeated TACE, sorafe-
nib, and chemotherapy. Moreover, it also showed similar
survival outcomes to those of the good prognostic
groups, such as patients with complete response to
TACE or those undergoing surgery with incomplete
TACE.
TACE is widely adopted as the current standard of
care for HCC patients at BCLC intermediate stage. Add-
itionally, it might be indicated for patients with early
stage HCCs that are unresectable or ineligible for local
ablative therapies such as RFA or PEI due to tumor loca-
tion or other medical conditions. Although complete re-
sponse to TACE has not yet been defined in radiological
findings, compact lipiodolisation is an important goal of
TACE. Cabibbo et al. [25] reported that a complete
radiological response after TACE significantly increases
OS, and thus proposed utilizing the observation as a sur-
rogate treatment endpoint. Kim et al. [26] indicated that
compact lipiodol uptake following TACE predicted fa-
vorable survival outcomes for unresectable HCC. The 1-
year and 5-year OS rates of patients with compact lipio-
dolisation were 93 % and 52 %, respectively, versus 61 %
and 17 %, respectively, in patients with noncompact
lipiodolisation. Similarly, in our current study, the OS
rates of group 1 patients with complete response to
TACE at 1 and 5 years were 96 % and 53 %, respectively.
In addition, only 14 % of the enrolled patients in this
study achieved a complete response after 1–4 sessions of
repeated TACE. Furthermore, approximately 40 % of the
patients were in stage 0, and almost 80 % had tumors
<3 cm, suggesting that group 1 patients had relatively
lower BCLC stages and smaller tumors than those in the
incomplete response groups. Therefore, although group
3 patients, who received SABR after incomplete re-
sponse to TACE, might have had poorer prognostic fac-
tors than group 1 patients, similar OS rates were
observed between the 2 groups.
Since a compact radiological response after TACE sig-
nificantly increases OS, technical improvements and re-
finements have been described for transarterial
administrative methods [3, 27]. However, many patients
still experience incomplete response after TACE, espe-
cially in cases of tumors >3 cm [28]. Several studies [29–
32] have shown that the combination of TACE and other
modalities, mainly surgery, RFA, PEI, or RT, was associ-
ated with higher survival rates. According to a prospect-
ive cohort study by Lee et al. [30], in which surgical
resection after primary TACE was compared with TACE
alone, the OS rate was significantly higher for the surgi-
cal resection group than for the TACE alone group (5-
year OS rate, 56 % vs. 23 %). Studies on TACE plus RFA
showed that patients in the TACE plus RFA group had
better LC rates than patients in the TACE alone group
[31], and better OS rates than patients in the RFA alone
group [32]. TACE plus RFA have also been reported to
provide similar OS rates to those achieved with surgical
resection [33]. Several randomized trials were conducted
to compare TACE plus PEI and TACE alone [34–36],
suggesting that TACE plus PEI performed better than ei-
ther TACE or PEI alone, and the reported 3-year OS
rates for TACE plus PEI were approximately 35 %–65 %.
In our current study, group 2 patients underwent sur-
gery, RFA, or PEI after incomplete TACE. This group
only included patients with CTP class A. Our findings
suggested that TACE might have been performed as a
bridge therapy in patients who were initially eligible for
curative treatments and subsequently underwent add-
itional surgery. Also, group 2 patients had significantly
lower CTP scores than the non-curative treatment group
4 patients. Therefore, group 2 patients might initially
have had good prognostic factors, and our results also
indicated a significant survival benefit in this group
compared with group 4. Additionally, although not sta-
tistically significant, group 2 consisted of patients with
relatively lower CTP scores compared to group 3, and
smaller tumors compared to groups 3 and 4. Therefore,
although group 3 patients might have had poorer prog-
nostic factors than group 2 patients, similar OS rates
were observed.
The benefit of additional 3D-CRT to incomplete TACE
over TACE alone in unresectable HCC has also been re-
ported. Meng et al. [10] conducted a meta-analysis of 17
trials, including 5 randomized controlled and 12 non-
randomized controlled studies. Although TACE plus RT
showed significantly improved survival and tumor re-
sponse compared with TACE alone in this meta-analysis,
none of the 5 randomized trials reported the random al-
location sequence in detail, and most of the original
studies included were published in Chinese, making gen-
eral acceptance challenging. On the other hand, in a
retrospective study, Shim et al. [5] reported that a com-
bination of 3D-CRT and incomplete TACE significantly
improved survival rates compared with TACE alone.
Their study included single tumors ≥5 cm, and the 2-
year OS rates of the TACE plus RT and TACE alone
groups were 37 % and 14 %, respectively. The combin-
ation of SABR and TACE has previously been studied by
Honda et al. [21]. Their results showed that SABR com-
bined with TACE was safe and effective for loco-regional
treatments, increasing both LC and OS compared with
TACE alone. The 1-year and 3-year OS rates for the
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SABR group were 100 % and 100 %, respectively,
whereas the corresponding rates for the TACE group
were 89 %, and 66 %, respectively. Although excellent
OS rates were reported, patient selection was very strict,
with only solitary tumors and small tumors ≤3 cm in-
cluded. Our results also indicated a significant survival
benefit of TACE plus SABR (group 3) over TACE alone
(group 4) with similar baseline characteristics between
the 2 groups.
There is not enough evidence to establish any combin-
ation therapy as a standard treatment for HCC after in-
complete TACE. In our study, combining SABR to
TACE offered similar survival outcomes to TACE and
curative treatments, and survival benefits over repeated
TACE, suggesting that SABR might be recommended as
a treatment modality after TACE failure. Furthermore,
SABR, being a noninvasive procedure, might be more
advantageous than other invasive curative modalities
such as surgery, RFA, or PEI. However, since this was a
retrospective study, patients were not controlled with re-
spect to variable prognostic factors. Additionally, the
dose and fractionation schedules of SABR and the num-
ber of previous TACE sessions prior to SABR are still
not well defined and are yet to be determined. There-
fore, further randomized trials are needed to validate
our results before SABR can be recommended routinely.
Hence, based on the results of this study, a multicenter
randomized controlled trial is being planned to investi-
gate the potential benefits of SABR as an alternative mo-
dality in the treatment of HCC after incomplete TACE.
Conclusions
Patients treated with SABR after incomplete TACE had
similar survival outcomes to those achieving complete
response to TACE or those receiving curative treatments
such as surgery, RFA, or PEI after incomplete TACE.
The addition of SABR also had a significant survival
benefit compared to repetitive TACE treatments. The
present retrospective study showed that about 20 % of
the patients initially treated with TACE met the eligibil-
ity criteria for curative SABR treatments, and may bene-
fit from further treatments of SABR. Therefore, SABR
might be considered an alternative treatment modality
following TACE failure.
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